Advanced search
Publication Cover
Journal of Medical Economics Volume 15, 2012 - Issue 2
Submit an article Journal homepage
1,136
Views
20
CrossRef citations to date
0
Altmetric
Original Article

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients

Chureen T. CarterJanssen Scientific Affairs LLC, Horsham, PAUSACorrespondence[email protected]
,
Arun K. ChangolkarSOAL PharmaTech Solutions LLC, Wilmington, DEUSA
&
R. Scott McKenzieJanssen Scientific Affairs LLC, Horsham, PAUSA
Pages 332-339 | Accepted 09 Dec 2011, Published online: 06 Jan 2012

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Kohei Mizuno, Yuri Ikeuchi-Takahashi, Yoshiyuki Hattori & Hiraku Onishi. (2021) Preparation and evaluation of conjugate nanogels of glycyl-prednisolone with natural anionic polysaccharides as anti-arthritic delivery systems. Drug Delivery 28:1, pages 136-144.
Read now
Julio Martinez-Cutillas, Carme Alerany-Pardo, Joaquín Borrás-Blasco, Antonio Broto-Sumalla, Amparo Burgos-SanJosé, Consuelo Climent-Bolta, Vicente Escudero-Vilaplana, María Anunciación Fernández-Fuente, Mónica Ferrit-Martin, Pilar Gómez-Germá, José Manuel Martínez-Sesmero, Jesús Mayorga-Pérez, Belén Menchén-Viso, Javier Merino-Alonso, Josefa Polache-Vengud & Amelia Sánchez-Guerrero. (2015) The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 851-858.
Read now
Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah & David J. Harrison. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics 18:5, pages 376-389.
Read now
Jeffrey R. Curtis, Vernon F. Schabert, Jason Yeaw, Jonathan R. Korn, Caroleen Quach, David J. Harrison, Huifeng Yun, George J. Joseph & David Collier. (2014) Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. Journal of Medical Economics 17:8, pages 555-566.
Read now
Fiorenzo Santoleri, Paola Sorice, Ruggero Lasala, Rosa Carmela Rizzo & Alberto Costantini. (2014) Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis. Journal of Medical Economics 17:5, pages 320-325.
Read now
Machaon Bonafede, George J. Joseph, Nicole Princic & David J. Harrison. (2013) Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. Journal of Medical Economics 16:9, pages 1120-1128.
Read now

Articles from other publishers (14)

Adrienn Markovics, Ken S. Rosenthal, Katalin Mikecz, Roy E. Carambula, Jason C. Ciemielewski & Daniel H. Zimmerman. (2021) Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models. Biomedicines 10:1, pages 44.
Crossref
Ahmad Gholami, Jassem Azizpoor, Elham Aflaki, Mehdi Rezaee & Khosro Keshavarz. (2021) Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. BioMed Research International 2021, pages 1-12.
Crossref
Clélia Monchablon, Henri Gondé, Sophie Pouplin, Rémi Varin, Olivier Vittecoq & Thierry Lequerré. (2019) Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Clinical Rheumatology 39:1, pages 207-216.
Crossref
Anagha Nadkarni, Donna McMorrow, Robert Fowler & David Smith. (2017) Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. Journal of Comparative Effectiveness Research 6:8, pages 659-669.
Crossref
Thomas DelateRoxanne MeyerDaniel Jenkins. (2017) Patterns of Care for Biologic-Dosing Outliers and Nonoutliers in Biologic-Naive Patients with Rheumatoid Arthritis. Journal of Managed Care & Specialty Pharmacy 23:8, pages 798-808.
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang & Debra F. Eisenberg. (2016) Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes 3:4, pages 369-381.
Crossref
Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, George J. Joseph, David J. Harrison & Brian C. Sauer. (2016) Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Advances in Therapy 33:8, pages 1347-1359.
Crossref
Ying Liu, Liang Sun, Zhen Hou, Yundong Mao, Yugui Cui & Jiayin Liu. (2016) rhTNFR: Fc Suppresses the Development of Endometriosis in a Mouse Model by Downregulating Cell Proliferation and Invasiveness. Reproductive Sciences 23:7, pages 847-857.
Crossref
Stephen S. Johnston, Donna McMorrow, Amanda M. Farr, Paul Juneau & Sarika Ogale. (2015) Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic. Drugs - Real World Outcomes 2:1, pages 99-109.
Crossref
Ning Wu, Yuan-Chi (Daisy) Lee, Neel Shah & David J. Harrison. (2014) Cost of Biologics per Treated Patient across Immune-mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study. Clinical Therapeutics 36:8, pages 1231-1241.e3.
Crossref
Alejandro González Álvarez, Manuel Gómez Barrera, Joaquín Borrás Blasco & Emilio José Giner Serret. (2014) Adalimumab and Etanercept in the Treatment of Rheumatoid Arthritis and Spondyloarthropathies: Budget Impact Model of Dose Reduction. Journal of Pharmacy and Nutrition Sciences 4:3, pages 170-176.
Crossref
Kathy J. Wheeler, Mary Ellen Roberts & Mary B. Neiheisel. (2014) Medication adherence part two: Predictors of nonadherence and adherence. Journal of the American Association of Nurse Practitioners 26:4, pages 225-232.
Crossref
Rieke Alten & Filip van den Bosch. (2014) Dose optimization of infliximab in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases 17:1, pages 5-18.
Crossref
Christine A. McBurney & Ernest R. Vina. (2012) Racial and Ethnic Disparities in Rheumatoid Arthritis. Current Rheumatology Reports 14:5, pages 463-471.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.